Medicinal preparation for assisting treatment of gastric cancer and application of medicinal preparation

Abstract

The invention provides a medicinal preparation for assisting gastric cancer treatment and application thereof, and belongs to the technical field of tumor treatment. The invention aims to significantly improve the effect of oxaliplatin in treatment of gastric cancer, especially to reduce the drug resistance of gastric cancer cells to oxaliplatin by using cosmosiin. The pharmaceutical preparation comprises cosmosiin and pharmaceutically acceptable auxiliary materials, the concentration range of the cosmosiin is 25-100 [mu] M, and the cosmosiin is used for enhancing the anti-cancer effect of oxaliplatin. The pharmaceutical preparation provided by the invention can effectively improve the clinical application effect of oxaliplatin in gastric cancer treatment, especially has important significance in dealing with oxaliplatin drug resistance, and provides a new treatment choice for gastric cancer patients.

Description

Technical Field

[0001] The present invention relates to the technical field of tumor treatment, and particularly to a pharmaceutical preparation for assisting in the treatment of gastric cancer and its application. Background Art

[0002] Gastric cancer is a common digestive tract malignant tumor, and its incidence and mortality rates are both among the top. The clinical treatment methods of gastric cancer mainly include surgical resection, chemotherapy, radiotherapy, etc. However, due to the non-obvious early symptoms of gastric cancer, many patients are already in the middle and late stages when diagnosed, missing the best opportunity for surgical treatment, resulting in limited surgical effects. For advanced gastric cancer, chemotherapy is still one of the main treatment means.

[0003] Oxaliplatin is a chemotherapy drug widely used in gastric cancer and belongs to the third-generation platinum-based chemotherapy drugs. Oxaliplatin shows good curative effects in the treatment of gastric cancer, especially in patients with inoperable advanced gastric cancer. However, there is a problem of drug resistance during its use. The drug resistance of gastric cancer patients to Oxaliplatin has become a major challenge in treatment. The drug resistance phenomenon directly affects the chemotherapy effect, leading to treatment failure and reducing the survival rate of patients. Therefore, studying new drug combinations or adjuvant treatment strategies, especially reversing drug resistance through natural drugs, has become an important direction in current tumor treatment research.

[0004] Cosmosiin is a flavonoid compound, also known as apigenin-7-glucoside. Existing reports show that cosmosiin has various biological activities, such as anti-inflammatory and antioxidant stress activities. At the same time, existing studies have found that cosmosiin has a significant inhibitory effect on human cervical cancer cells. However, there have been no reports on the role of cosmosiin in the treatment of gastric cancer. Summary of the Invention

[0005] The purpose of the present invention is to provide a pharmaceutical preparation for assisting in the treatment of gastric cancer. By combining the use of cosmosiin and Oxaliplatin, it aims to effectively reverse the drug resistance of gastric cancer cells to Oxaliplatin, thereby improving the treatment effect of Oxaliplatin.

[0006] To achieve the above purpose, the present invention provides the following technical solutions:

[0007] In the first aspect, the present invention provides a pharmaceutical preparation for assisting in the treatment of gastric cancer, which is characterized in that the pharmaceutical preparation is composed of cosmosiin and pharmaceutically acceptable excipients. As the main active ingredient, cosmosiin can, on the one hand, produce a certain inhibitory effect on gastric cancer cells, and on the other hand, can be used as an adjuvant agent to overcome the drug resistance of gastric cancer cells to Oxaliplatin, thereby improving the chemotherapy effect.

[0008] The excipients can provide stability and convenient usage for the pharmaceutical preparation, ensuring the bioavailability and effectiveness of the drug in the body.

[0009] Preferably, in the pharmaceutical preparation, the concentration of cosmidin is 25 μM - 100 μM.

[0010] In a second aspect, the present invention provides the use of cosmidin in the preparation of a sensitizer for enhancing the therapeutic effect of oxaliplatin in the treatment of gastric cancer. Specifically, cosmidin reverses the drug resistance of oxaliplatin by inhibiting the MDR1 protein, enabling it to resume its inhibitory effect on the proliferation and migration of gastric cancer cells, thereby enhancing the therapeutic effect.

[0011] Preferably, the gastric cancer treatment is to inhibit the proliferation of gastric cancer cells and inhibit the migration of gastric cancer cells.

[0012] Preferably, in the sensitizer, the concentration of cosmidin is not less than 25 μM.

[0013] In a third aspect, the present invention provides the use of cosmidin as a sensitizer for oxaliplatin in the treatment of gastric cancer in the preparation of a drug for the treatment of gastric cancer. By using cosmidin and oxaliplatin in combination, the pharmaceutical preparation can effectively enhance the anti-gastric cancer effect of oxaliplatin.

[0014] Preferably, in the drug for the treatment of gastric cancer, the concentration of cosmidin is not less than 25 μM, and the concentration of oxaliplatin is not less than 5 μg / ml.

[0015] Preferably, the drug for the treatment of gastric cancer is used to inhibit the proliferation of gastric cancer cells and inhibit the migration of gastric cancer cells.

[0016] In a fourth aspect, the present invention provides the application of a composition composed of cosmidin and oxaliplatin in the preparation of a drug for the treatment of gastric cancer. In the composition, the concentration of cosmidin is not less than 25 μM, and the concentration of oxaliplatin is not less than 5 μg / ml. This composition can effectively combine the anti-cancer effect of oxaliplatin with the sensitizing effect of cosmidin, enhance the effect of the chemotherapeutic drug on drug-resistant gastric cancer cells, inhibit cell proliferation and migration, and significantly improve the therapeutic effect.

[0017] Preferably, the drug for the treatment of gastric cancer is used to inhibit the proliferation of gastric cancer cells and inhibit the migration of gastric cancer cells.

[0018] In a fifth aspect, the present invention provides a composition for the treatment of gastric cancer, which is composed of cosmidin and oxaliplatin; in the composition, the concentration of cosmidin is not less than 5 μg / ml, and the concentration of oxaliplatin is not less than 5 μg / ml.

[0019] In a sixth aspect, the present invention provides the use of a composition comprising cosmin and oxaliplatin in the preparation of a drug for inhibiting the proliferation and migration of gastric cancer cells in vitro. In the composition, the concentration of cosmin is not less than 25 μM, and the concentration of oxaliplatin is not less than 5 μg / ml. This composition can effectively synergistically inhibit the proliferation and migration of gastric cancer cells, thus providing a new treatment option for gastric cancer patients.

[0020] The beneficial effects of the present invention are as follows:

[0021] First of all, the present invention expands the new functions of cosmin. The present invention discovers that cosmin can effectively reverse the drug resistance of gastric cancer cells to chemotherapeutic drugs such as oxaliplatin, thereby expanding the application potential of cosmin as an anti-cancer sensitizer.

[0022] Secondly, by combining cosmin with oxaliplatin, the present invention significantly enhances the therapeutic effect of oxaliplatin on drug-resistant gastric cancer cells. Cosmin can effectively reverse the drug resistance of gastric cancer cells to oxaliplatin, making them regain sensitivity to oxaliplatin, thereby improving the effect of oxaliplatin in the treatment of inhibiting the proliferation and migration of gastric cancer cells.

[0023] In addition, cosmin in the present invention, as a natural plant-derived component, can reduce the side effects of drugs while enhancing the anti-cancer effect when combined with oxaliplatin. The low toxicity characteristics of cosmin make it an ideal sensitizer for oxaliplatin, thereby reducing the harm to the patient's body during chemotherapy. Through the pharmaceutical preparation of the present invention, the drug resistance of gastric cancer cells to chemotherapeutic drugs can be effectively overcome, continuously improving the effect of chemotherapeutic drugs in the treatment of gastric cancer, and further prolonging the survival period of patients and improving the quality of life. Description of the Drawings

[0024] Figure 1 It is the inhibitory effect of cosmin on the proliferation of SGC-7901 / L-OHP cells;

[0025] Among them, in Figure (A), it is the inhibitory situation of cosmin on the proliferation of SGC-7901 / L-OHP cells after 24 hours of treatment;

[0026] In Figure (B), it is the inhibitory situation of cosmin on the proliferation of SGC-7901 / L-OHP cells after 48 hours of treatment;

[0027] Figure 2 It is the inhibitory effect of the combined use of oxaliplatin and cosmin on the proliferation of SGC-7901 / L-OHP cells. The figure shows the inhibitory effects of different concentrations of oxaliplatin combined with 25 μM cosmin on SGC-7901 / L-OHP drug-resistant cells;

[0028] Figure 3 Effect of the combined use of oxaliplatin and luteolin-7-O-glucoside on the migration ability of SGC-7901 / L-OHP cells. The number of migrated cells in the Transwell chamber assay for different treatment groups (control group, oxaliplatin alone group, oxaliplatin + luteolin-7-O-glucoside combination group) is shown in the figure.

[0029] Figure 4 Effect of the combined use of oxaliplatin and luteolin-7-O-glucoside on the expression of MDR1 protein in SGC-7901 / L-OHP cells. The expression levels of MDR1 protein in different treatment groups (control group, oxaliplatin alone group, oxaliplatin + luteolin-7-O-glucoside combination group) after 24 hours were detected by Western blot and are shown in the figure. Detailed implementation mode

[0030] To make the objectives, technical solutions and advantages of the present invention clearer, the present invention will be further described in detail below in conjunction with embodiments, but the present invention is not limited to the shown implementation scope.

[0031] Example 1

[0032] Inhibitory effect of luteolin-7-O-glucoside at different concentrations on the growth of gastric cancer drug-resistant cells

[0033] Experimental materials:

[0034] Cell line: SGC-7901 / L-OHP cells (oxaliplatin-resistant gastric cancer cell line).

[0035] Culture medium and reagents: RPMI-1640 medium (containing 10% fetal bovine serum (FBS)), PBS (phosphate buffer), 0.25% trypsin, luteolin-7-O-glucoside (Merck Sigma), and CCK-8 kit.

[0036] Experimental equipment: 96-well culture plate, 37 °C, 5% CO 2 Incubator, cell counting chamber, pipette, sterile culture flask, sterile pipette tips, pipettes, pipettors, etc.

[0037] Experimental steps:

[0038] 1. Inoculate SGC-7901 gastric cancer cells into RPMI-1640 medium containing 10% fetal bovine serum (FBS) and culture in an incubator at 37 °C, 5% CO 2 until the cells grow to the logarithmic growth phase.

[0039] 2. Wash the cells once with PBS, collect the cells and adjust the cell concentration to 1×10 5cells / mL.

[0040] 3. In each well of a 96-well plate, inoculate 100 μL of cell suspension (about 1×10 4 cells), ensuring uniform distribution of cells in each well.

[0041] 4. After cell inoculation, continue to place the 96-well plate in an incubator and let it stand for 24 hours to ensure cell attachment and stable growth.

[0042] 5. Prepare cosmosin solutions at different concentrations (25 μM, 50 μM, 75 μM, 100 μM), and add them to each well. The volume of the added drug is 100 μL. At the same time, set up a control group with only medium added, and perform 3 replicates for each concentration and the control group.

[0043] 6. Place the treated 96-well plate in a constant temperature incubator at 37°C and 5% CO 2 for 24 and 48 hours.

[0044] 7. After 24 and 48 hours of treatment, add 10 μL of CCK-8 reagent to each well, and continue to place the 96-well plate in an incubator at 37°C and 5% CO 2 for 3 hours until the color change is stable.

[0045] 8. Use an enzyme-linked immunosorbent assay (ELISA) reader to measure the absorbance (OD value) of each well at a wavelength of 450 nm, record the data, and calculate the relative cell growth inhibition rate.

[0046] Experimental results:

[0047] The results obtained in this example are as shown in Figure 1 A and Figure 1 B. As can be seen from Figure 1 A and Figure 1 B, cosmosin can produce a certain degree of inhibitory effect on SGC-7901 / L-OHP cells, but the overall inhibitory effect is relatively general. This shows that when using cosmosin alone to inhibit gastric cancer drug-resistant cells, although a certain inhibitory effect can be produced, the inhibitory effect is not particularly ideal.

[0048] Example 2

[0049] The above example proved that when cosmosin is used alone, it can inhibit SGC-7901 / L-OHP cells to a certain extent, but the effect is general. Therefore, in this example, the inhibitory effect of combining cosmosin with oxaliplatin on SGC-7901 / L-OHP cells was detected.

[0050] Since 25 μM cosmosin alone has basically no inhibitory effect on SGC-7901 / L-OHP cells, this concentration was selected for subsequent experiments to conveniently evaluate the enhancing effect of cosmosin on oxaliplatin sensitivity.

[0051] The experimental materials were the same as those in Example 1, and oxaliplatin was purchased from Sigma.

[0052] Experimental procedure:

[0053] 1. SGC-7901 / L-OHP gastric cancer cells were respectively inoculated into RPMI-1640 medium containing 10% fetal bovine serum (FBS) and cultured in a constant temperature incubator at 37 °C and 5% CO 2 until the cells grew to the logarithmic growth phase.

[0054] 2. The cells were washed once with PBS, collected, and the cell concentration was adjusted to 1×10 5 cells / mL.

[0055] 3. 100 μL of cell suspension (about 1×10 4 cells) was inoculated into each well of a 96-well plate, ensuring uniform distribution of cells in each well.

[0056] 4. After cell inoculation, the 96-well plate was continued to be placed in the incubator and left standing for 24 hours to ensure cell attachment and stable growth.

[0057] 5. The cells were treated according to the following groups: oxaliplatin single-use group (5, 10, 20 μg / ml), oxaliplatin + cosmosin group (25 μM cosmosin + 5, 10, 20 μg / ml oxaliplatin), and a control group with only medium added was set up. Each concentration and the control group were replicated 3 times.

[0058] 6. The treated 96-well plate was placed in a constant temperature incubator at 37 °C and 5% CO 2 and cultured for 48 hours.

[0059] 7. After 48 hours of treatment, 10 μL of CCK-8 reagent was added to each well, and the 96-well plate was continued to be placed in an incubator at 37 °C and 5% CO 2 and cultured for 3 hours until the color change was stable.

[0060] 8. The absorbance (OD value) of each well was measured at a wavelength of 450 nm using a microplate reader, and the data was recorded and the relative cell growth inhibition rate was calculated.

[0061] Experimental results:

[0062] The results obtained in this example are as Figure 2As shown, the inhibitory effects of different concentrations of oxaliplatin combined with acaciin on SGC-7901 / L-OHP drug-resistant cells were demonstrated. The specific data are as follows: in the 5 μg / ml oxaliplatin group, the relative cell inhibition rate was 10.73% ± 1.12%; in the combination group of 5 μg / ml oxaliplatin and 25 μM acaciin, the relative cell inhibition rate was 22.66% ± 0.97%; in the 10 μg / ml oxaliplatin group, the relative cell inhibition rate was 15.84% ± 1.64%; in the combination group of 10 μg / ml oxaliplatin and 25 μM acaciin, the relative cell inhibition rate was 48.31% ± 1.78%; in the 20 μg / ml oxaliplatin group, the relative cell inhibition rate was 28.91% ± 2.33%; in the combination group of 20 μg / ml oxaliplatin and 25 μM acaciin, the relative cell inhibition rate was 72.34% ± 2.17%.

[0063] It can be clearly seen from the above results that compared with the groups using different concentrations of oxaliplatin alone, the combined treatment groups supplemented with 25 μM acaciin showed significantly higher cell inhibition effects in the treatment with oxaliplatin at various concentrations. This indicates that acaciin significantly enhanced the inhibitory effect of oxaliplatin on the proliferation of SGC-7901 / L-OHP drug-resistant cells. Especially when 20 μg / ml oxaliplatin was combined with 25 μM acaciin, the inhibition rate reached 72.34%, which was much higher than the effect of oxaliplatin alone.

[0064] This result indicates that acaciin may effectively reverse the drug resistance of SGC-7901 / L-OHP drug-resistant cells through a certain mechanism, enhance the inhibitory effect of oxaliplatin on the proliferation of gastric cancer cells, and has the potential to be used as a sensitizer for combined chemotherapy.

[0065] Example 3

[0066] To further verify the sensitizing effect of acaciin, the present invention detected the effect of the combination of acaciin and oxaliplatin on the migration ability of SGC-7901 / L-OHP drug-resistant cells.

[0067] Experimental materials:

[0068] Cell line: SGC-7901 / L-OHP cells (oxaliplatin-resistant gastric cancer cell line).

[0069] Culture media and reagents: RPMI-1640 medium (containing 10% fetal bovine serum (FBS)), RPMI-1640 medium (serum-free), PBS (phosphate buffer), 0.25% trypsin, Luteolin-7-O-glucoside (Merck Sigma), Oxaliplatin (L-OHP, Merck Sigma), crystal violet dye, 4% paraformaldehyde.

[0070] Experimental equipment: Transwell chambers, 24-well plates, inverted microscopes, image analysis software (ImageJ), 37°C, 5% CO 2 incubator, cell counting plates, pipettes, sterile culture flasks, sterile pipette tips, pipettes, pipettors, etc.

[0071] Experimental procedures:

[0072] 1. Inoculate SGC-7901 / L-OHP cells into RPMI-1640 medium containing 10% fetal bovine serum (FBS) and culture in an incubator at 37°C and 5% CO 2 until the cells grow to the logarithmic growth phase.

[0073] 2. Prepare cell suspensions using serum-free medium for the control group, serum-free medium containing 20 μg / ml oxaliplatin for the oxaliplatin single-use group, and serum-free medium containing 25 μM luteolin and 20 μg / ml oxaliplatin for the oxaliplatin + luteolin group.

[0074] 3. Inoculate the cells into the upper chamber of the Transwell chamber, 200 μl per well, with 1×10 4 cells, and add medium containing 10% fetal bovine serum to the lower chamber of the Transwell chamber as an attracting factor to induce cell migration.

[0075] 4. Place the inoculated Transwell chamber in the incubator and continue to culture for 24 hours.

[0076] 5. After 24 hours, gently wash the chamber with PBS to remove non-migrated cells, and fix the cells that have migrated to the bottom of the membrane with 4% paraformaldehyde for 20 minutes.

[0077] 6. Stain the migrated cells with crystal violet staining solution. After 15 minutes, remove the excess dye and wash it clean with PBS.

[0078] 7. Observe the migrated cells on the membrane of the Transwell chamber using an inverted microscope, randomly select fields of view to take images, and randomly select 5 fields of view to record the number of migrated cells.

[0079] Experimental results:

[0080] From Figure 3 the results, it can be seen that there are significant differences in the average number of visual field cells in each group. The average number of visual field cells in the control group is 120, the average number of visual field cells in the oxaliplatin single - use group drops to 81, while the average number of visual field cells in the oxaliplatin + luteolin - 7 - O - glucoside group significantly decreases to 33.

[0081] These results indicate that when oxaliplatin is used alone, it can inhibit the migration ability of SGC - 7901 / L - OHP cells to a certain extent, but its effect is relatively poor. When luteolin - 7 - O - glucoside is used in combination with oxaliplatin, the migration ability of cells significantly decreases, showing an obvious inhibitory effect. This indicates that luteolin - 7 - O - glucoside can enhance the anti - migration effect of oxaliplatin on SGC - 7901 / L - OHP cells.

[0082] Since 25 μM luteolin - 7 - O - glucoside has basically no inhibitory effect on SGC - 7901 / L - OHP cells, luteolin - 7 - O - glucoside mainly enhances the inhibitory effect of oxaliplatin on cell migration by reducing the drug resistance of SGC - 7901 / L - OHP cells to oxaliplatin. This result further supports the potential of luteolin - 7 - O - glucoside as an oxaliplatin sensitizer, suggesting that it is an effective strategy to enhance the inhibitory effect of oxaliplatin on gastric cancer cell migration by reversing drug resistance.

[0083] Example 4

[0084] To further detect the effect of luteolin - 7 - O - glucoside in reducing the drug resistance of gastric cancer drug - resistant cells to oxaliplatin, in this example, the protein expression level of multidrug - resistant - related protein 1 (MRP1) was detected.

[0085] Cell line: SGC - 7901 / L - OHP cells (oxaliplatin - resistant gastric cancer cell line).

[0086] Culture medium and reagents: RPMI - 1640 medium (containing 10% fetal bovine serum (FBS)), RPMI - 1640 medium (serum - free), PBS (phosphate - buffered saline), 0.25% trypsin, luteolin - 7 - O - glucoside (Luteolin - 7 - O - glucoside, Merck Sigma), oxaliplatin (L - OHP, Merck Sigma), RIPA lysis buffer, loading buffer, 5% skim milk, TBST (TBS buffer containing 0.1% Tween - 20), ECL luminescence solution, MDR1 antibody, β - actin antibody.

[0087] Experimental equipment: electrophoresis apparatus, electro - transfer apparatus, PVDF membrane, incubation box, 6 - well plate, 37 °C, 5% CO 2Thermostatic incubator, cell counting chamber, pipette, sterile culture flask, sterile pipette tips, pipettes, pipettors, etc.

[0088] Experimental procedures:

[0089] 1. Inoculate SGC-7901 / L-OHP cells into RPMI-1640 medium containing 10% fetal bovine serum (FBS) and culture them in an incubator at 37°C and 5% CO 2 until the cells grow to the logarithmic growth phase.

[0090] 2. Inoculate the cells into a 6-well plate. After the cell density reaches over 80%, treat the cells according to the following groups: replace the control group with RPMI-1640 medium, replace the oxaliplatin single-use group with RPMI-1640 medium containing 20 μg / ml oxaliplatin, and replace the oxaliplatin + cosmosin group with RPMI-1640 medium containing 25 μM cosmosin and 20 μg / ml oxaliplatin.

[0091] 3. Place the treated 6-well plate into a thermostatic incubator at 37°C and 5% CO 2 and culture for 24 hours.

[0092] 4. Remove the medium, wash with PBS, and then use RIPA lysis buffer to extract the protein samples of each group. After detecting the protein concentration, adjust the proteins of each group to the same concentration with RIPA lysis buffer, add loading buffer, and boil in a water bath for 10 min to fully denature the proteins.

[0093] 5. After loading the protein samples, perform electrophoresis at a constant voltage of 120V until the electrophoresis is completed. Install the electrotransfer clip and transfer at 250 mA for 1.5 hours.

[0094] 6. After the electrotransfer is completed, take out the PVDF membrane, block it in 5% skim milk for 2 h, and then incubate it overnight at 4°C with MDR1 and β-actin antibodies in an incubation box.

[0095] 7. After washing the membrane with TBST, add the secondary antibody and incubate it on a shaker at room temperature for 1.5 hours. After washing the membrane with TBST, use ECL luminescent solution for luminescence color development.

[0096] Experimental results:

[0097] From Figure 4 the results, it can be seen that compared with the control group and the oxaliplatin single-use group, the protein expression level of MDR1 in the oxaliplatin + cosmosin group decreased significantly, which further verified that cosmosin can effectively reduce the drug resistance of SGC-7901 / L-OHP cells to oxaliplatin.

Claims

1. A pharmaceutical preparation for assisting the treatment of gastric cancer, characterized in that: The pharmaceutical preparation consists of cosmos glycoside and pharmaceutically acceptable excipients.

2. A pharmaceutical preparation for assisting the treatment of gastric cancer according to claim 1, characterized in that: In the pharmaceutical preparation, the concentration of cosmos glycoside is 25 μM-100 μM.

3. Use of cosmos glycoside in the preparation of a sensitizer for improving the therapeutic effect of oxaliplatin on gastric cancer.

4. The use of cosmos glycoside according to claim 3 in the preparation of a sensitizer for improving the therapeutic effect of oxaliplatin on gastric cancer, characterized in that: The gastric cancer treatment effect is the effect of inhibiting the proliferation of gastric cancer cells and inhibiting the migration of gastric cancer cells.

5. The use of cosmos glycosides according to claim 4 in the preparation of an oxaliplatin gastric cancer treatment sensitizer, characterized in that: In the sensitizer, the concentration of cosmos glycoside is not less than 25 μM.

6. Use of cosmos glycoside as a sensitizer for oxaliplatin in the treatment of gastric cancer in the preparation of drugs for the treatment of gastric cancer.

7. Use of cosmos glycoside as an oxaliplatin gastric cancer treatment sensitizer in the preparation of a gastric cancer treatment drug according to claim 6, characterized in that: The concentration of cosmos glycoside in the gastric cancer treatment drug is not less than 25 μM, and the concentration of oxaliplatin is not less than 5 μg / ml.

8. Use of cosmos glycoside as an oxaliplatin gastric cancer treatment sensitizer in the preparation of a gastric cancer treatment drug according to claim 7, characterized in that: The gastric cancer therapeutic drug is used for inhibiting the proliferation of gastric cancer cells and inhibiting the migration of gastric cancer cells.

9. Use of a composition composed of cosmos glycoside and oxaliplatin in the preparation of a drug for treating gastric cancer, characterized in that: In the composition, the concentration of cosmos glycoside is not less than 25 μM, and the concentration of oxaliplatin is not less than 5 μg / ml.

10. Use of the composition of cosmos glycoside combined with oxaliplatin according to claim 9 in the preparation of a drug for treating gastric cancer, characterized in that: The gastric cancer therapeutic drug is used for inhibiting the proliferation of gastric cancer cells and inhibiting the migration of gastric cancer cells.

Images